Each of these compounds were shown to inhibit both in vitro activity of LSD1 and cell proliferation in LNCaP prostate cancer cells (Table 1, Additional file 1: Figure S2, Figure S3) but with many fold increase in potency over the tranylcypromine base compound. This evidence concerns the gene KDM1A and prostate carcinoma.